

Internal Communication

Eurofins Advinus expands its operation to Hyderabad

19 December 2022

I am pleased to inform that on 16th December 2022 we closed the deal and acquired the facilities, equipment and other assets of a company in Genome Valley, Hyderabad, India. This acquisition marks our entry into the State of Telangana. The facilities acquired consists of a 15-acre site on which about 90,000 sq.ft. of modern labs and offices are already built. The acquisition comes will fully functional labs in the areas of synthetic organic chemistry, analytical R&D, bioanalytical (large and small molecule), in-vivo pharmacology and toxicology, and formulation R&D. Eurofins Advinus now has a new and significant campus in Hyderabad that complements our existing operations in Bangalore with additional capacity in discovery chemistry, analytical chemistry and bioanalytical services along with our invivo offering. Within the next few months, the facilities will be modified to offer added portfolio of services. Key among these would be invitro biology and in-vivo pharmacology in the areas of Oncology / Immuno-Oncology and Infectious Diseases. We will also be expanding on our existing ADME capabilities in Bangalore through additional ADME offerings from Hyderabad. Over time we expect many new services to roll out from our Hyderabad Campus.

In addition to our site in Peenya, Bangalore, the new Hyderabad campus is envisaged to be the second showcase site of Eurofins Advinus.

The leadership team in Bangalore is already working to recruit new talent in Hyderabad and make the Hyderabad campus operational as soon as possible. If you wish to consider Hyderabad as an option, please discuss with your supervisor and post his / her consent reach out to me or hr.hyd@advinus.com.

Regards
Rajiv Malik
CEO and MD
Eurofins Advinus (P) Limited

Some site pictures of the new Eurofins Advinus Campus in Hyderabad:



